xRead - Nasal Obstruction (September 2024) Full Articles

20426984, 2021, 3, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/alr.22741 by Stanford University, Wiley Online Library on [01/07/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

626

International consensus statement on rhinosinusitis

No side effects, Sinuband FP and Sinuband better than Merocel for polyps Decrease in postoperative intervention.

1 case of ocular irritation and 1 nasal irritation. 21/24 successfully inserted. NP size decreased. Need for revision surgery eliminated in 64%

5 patients with recurrent NP treated with non-US FDA approved stent Safety of device No systemic absorption or adrenal suppression.

100% insertion rate 90% of patient very satisfied with experience

Improvement in SNOT-20 and endoscopic scores

Decreased polyposis and adhesions, no difference in MT lateralization No device related adverse effects No systemic absorption.

Study Year LOE Study Design Study Groups Clinical Endpoint Conclusions Adriaensen 2251 2017 2 Single blind RCT

Decreased adhesions and polyposis. No safety concerns.

Improvement in SNOT-22 and RSDI Safety with no ocular risk. 1.1% adhesion rate 4.4% MT lateralization

10/10 successful implant insertion

Adhesions No significant difference

SNOT-22 and RSDI at 6 month Safety

Endoscopic follow up to 60 days

Marple 2237 2012 2 Prospective, multicenter, DBRCT using intrapatient control design (n = 105) ESS forCRS Postoperative interventions at 30days Endoscopy Safety

Feasibility of insertion and safety of device

Sinuband FP vs no packing, Sinuband without steroid

vs no packing and Mercoel vs no packing

Murr 2245 2011 2 Prospective multicenter intrapatient DBRCT (n = 43) ESS forCRS Endoscopic assessment at day 21 Safety. Unilateral (n = 10) or bilateral

Safety of device

Efficacy of device

second cohort 128 received Merogel R soaked with triamcinolone

First cohort of 146 received Merocel R in finger cot vs

(n = 40) stent placement.

Recurrent NP following ESS treated with non-US FDA approved stent

20 patients post ESS had stent inserted within 7 days postop

fluticasone propionate (FP)-eluting

implant, SinuBand FP

(non-US FDA approved)

Matheny 2252 2014 4 Prospective, single center, nonrandomized cohort study using Propel TM

Lavigne 1806 2014 4 Prospective, multicenter nonrandomized cohort study (n = 12)

Forwith 1612 2011 3 Prospective multicenter single cohort study (n = 50)

Ow 2253 2014 4 Prospective single center non-randomized cohort study

Xu 2163 2016 4 Retrospective sequential cohort study

Patients 274 – 548 nasal sides

27 patients – 54 sides

TABLE XII-24 (Continued)